An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2023-12-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study designed to evaluate the safety, tolerability,
pharmacokinetics, and anti-tumor activity of ceralasertib in Japanese patients with advanced
solid malignancies. Cycle 0 duration is 4 days and each cycle from Cycle 1 has a duration of
28 days.